Tandem Mass Spectrometry Has a Larger Analytical Range than Fluorescence Assays of Lysosomal Enzymes: Application to Newborn Screening and Diagnosis of Mucopolysaccharidoses Types II, IVA, and VI

KUMAR, AB, S MASI, F GHOMASHCHI, NK CHENNAMANENI, M ITO, CR SCOTT, F TURECEK, MH GELB and Zdeněk SPÁČIL. Tandem Mass Spectrometry Has a Larger Analytical Range than Fluorescence Assays of Lysosomal Enzymes: Application to Newborn Screening and Diagnosis of Mucopolysaccharidoses Types II, IVA, and VI. Clinical Chemistry. Washington, USA: Amer. Assoc. Clinical Chemistry, 2015, vol. 61, No 11, p. 1363-1371. ISSN 0009-9147. Available from: https://dx.doi.org/10.1373/clinchem.2015.242560.

Basic information

• Original name: Tandem Mass Spectrometry Has a Larger Analytical Range than Fluorescence Assays of Lysosomal Enzymes: Application to Newborn Screening and Diagnosis of Mucopolysaccharidoses Types II, IVA, and VI
• Authors: KUMAR, AB, S MASI, F GHOMASHCHI, NK CHENNAMANENI, M ITO, CR SCOTT, F TURECEK, MH GELB and Zdeněk SPÁČIL.
• Edition: Clinical Chemistry, Washington, USA, Amer. Assoc. Clinical Chemistry, 2015, 0009-9147.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• Impact factor: Impact factor: 7.457
• Doi: http://dx.doi.org/10.1373/clinchem.2015.242560
• UT WoS: 000364112200009

Abstract

BACKGROUND: There is interest in newborn screening and diagnosis of lysosomal storage diseases because of the development of treatment options that improve clinical outcome. Assays of lysosomal enzymes with high analytical range (ratio of assay response from the enzymatic reaction divided by the assay response due to nonenzymatic processes) are desirable because they are predicted to lead to a lower rate of false positives in population screening and to more accurate diagnoses. METHODS: We designed new tandem mass spectrometry (MS/MS) assays that give the largest analytical ranges reported to date for the use of dried blood spots (DBS) for detection of mucopolysaccharidoses type II (MPS-II), MPS-IVA, and MPS-VI. For comparison, we carried out fluorometric assays of 6 lysosomal enzymes using 4-methylumbelliferyl (4MU)-substrate conjugates. RESULTS: The MS/MS assays for MPS-II, -IVA, and -VI displayed analytical ranges that are 1-2 orders of magnitude higher than those for the corresponding fluorometric assays. The relatively small analytical ranges of the 4MU assays are due to the intrinsic fluorescence of the 4MU substrates, which cause high background in the assay response. CONCLUSIONS: These highly reproducible MS/MS assays for MPS-II, -IVA, and -VI can support multiplex newborn screening of these lysosomal storage diseases. MS/MS assays of lysosomal enzymes outperform 4MU fluorometric assays in terms of analytical range. Ongoing pilot studies will allow us to gauge the impact of the increased analytical range on newborn screening performance. (C) 2015 American Association for Clinical Chemistry